
    
      STUDY DESIGN This study will be performed at one investigational site in the UK. This is a
      single centre, prospective observational cohort study of HIV positive individuals on
      suppressive HAART with malignancy undergoing chemotherapy.

      ELIGIBILITY Individuals receiving HAART and diagnosed with either lymphoma or Kaposi's
      sarcoma receiving combination chemotherapy agents, which include the vinca alkaloids and
      taxanes, will be eligible for this study.
    
  